Nature Biotechnology
- 24, 1512 - 1514 (2006)
doi:10.1038/nbt1206-1512
Antibiotics—an investment worth making?Ralph E Christoffersen
Ralph Christoffersen is a General Partner at Morgenthaler Ventures, 4430 Arapahoe Avenue, Suite 220, Boulder, Colorado 80303, USA. Morgenthaler is an investor in Replidyne, Inc., and Christoffersen is a member of the Board of Directors of Replidyne. rchris@morgenthaler.com
Antibiotics markets are huge and the need for new classes of antibiotics is great, but the risks give investors pause.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
